Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NYSE | Common Stock
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH.
It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences.
The company was founded in 1781 and is headquartered in Tokyo, Japan.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | 29.07 Increased by +287.55% | 87.45 Decreased by -66.76% |
| Jul 31, 24 | 0.19 Decreased by -6.15% | - |
| May 9, 24 | -0.01 Decreased by -108.78% | -0.01 Increased by +54.23% |
| Feb 1, 24 | 33.79 Increased by +11.44 K% | 0.11 Increased by +31.04 K% |
| Oct 26, 23 | -15.50 Decreased by -11.62 K% | 0.14 Decreased by -10.86 K% |
| Jul 27, 23 | 0.20 Decreased by -19.39% | 0.12 Increased by +69.62% |
| May 22, 23 | 0.07 Increased by +373.06% | 0.05 Increased by +46.53% |
| Feb 2, 23 | 0.29 Increased by +82.37% | 0.28 Increased by +3.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 1.18 T Increased by +12.75% | 92.05 B Increased by +291.64% | Increased by +7.83% Increased by +269.98% |
| Jun 30, 24 | 1.21 T Increased by +15.81% | 95.25 B Increased by +298.31% | Increased by +7.88% Increased by +271.24% |
| Mar 31, 24 | 1.21 T Increased by +26.34% | 95.25 B Increased by +205.93% | Increased by +7.88% Increased by +142.15% |
| Dec 31, 23 | 1.11 T Increased by +1.33% | 105.72 B Decreased by -11.25% | Increased by +9.51% Decreased by -12.42% |
| Sep 30, 23 | 1.04 T Increased by +4.07% | -48.03 B Decreased by -177.79% | Decreased by -4.60% Decreased by -174.75% |
| Jun 30, 23 | 1.04 T Increased by +7.26% | -48.03 B Decreased by -145.74% | Decreased by -4.60% Decreased by -142.64% |
| Mar 31, 23 | 956.16 B Increased by +9.49% | 31.13 B Increased by +373.71% | Increased by +3.26% Increased by +349.98% |
| Dec 31, 22 | 1.10 T Increased by +21.66% | 119.13 B Increased by +106.21% | Increased by +10.86% Increased by +69.49% |